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Abstract 
 
   14-3-3σ, a gene upregulated by p53 in response to DNA damage, exists as part of a 
positive-feedback loop which activates p53 and is a human cancer epithelial marker 
downregulated in various cancer types. 14-3-3σ levels are critical for maintaining p53 
activity in response to DNA damage and regulating signal mediator such as Akt. Here, 
we identify Mammalian Constitutive Photomorphogenic 1 (COP1) as a novel E3 ubiquitin 
ligase for targeting 14-3-3σ through proteasome degradation. We show for the first time 
that COP9 signalosome subunit 6 (CSN6) associates with COP1 and is involved in 14-3-
3σ ubiquitin-mediated degradation. Mechanistic studies show that CSN6 expression 
leads to stabilization of COP1 through reducing COP1 self-ubiquitination and 
decelerating COP1’s turnover rate. We also show that CSN6-mediated 14-3-3σ 
ubiquitination is compromised when COP1 is knocked down. Thus, CSN6 mediates 14-
3-3σ ubiquitination through enhancing COP1 stability. Subsequently, we show that CSN6 
causes 14-3-3σ downregulation, thereby activating Akt and promoting cell survival by 
suppressing FOXO, an Akt target, transcriptional activity. Also, CSN6 overexpression 
leads to increased cell growth, transformation and promotes tumorigenicity. Significantly, 
14-3-3σ expression can correct the abnormalities mediated by CSN6 expression. These 
data suggest that the CSN6-COP1 axis is involved in 14-3-3σ degradation, and that 
deregulation of this axis will promote cell growth and tumorigenicity.  
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CHAPTER 1. INTRODUCTION 
   
1.1. COP9 signalosome 6 (CSN6), a multiprotein complex  
   The ubiquitin-proteasome pathway is important for controlling the abundance of 
proteins and plays an essential role in maintaining normal cellular functions. 
Dysregulation of ubiquitin-mediated proteolysis results in the development of a variety of 
human cancers (1). The evolutionarily conserved Constitutive Photomorphogenesis 9 
Signalosome (CSN) was originally identified from plant (Arabidopsis) mutants that mimic 
light-induced seedling development when grown in the dark (2-4). Mammalian COP9 
signalosome contains eight subunits (CSN1-CSN8), which share sequence homology 
with subunits of the ‘lid’ complex of the 26S proteasome (5). Because of the homology, 
the COP9 signalosome has been postulated to play a role in protein degradation. CSN6 
and CSN5 are the only two subunits that contain an MPN (Mpr1p and Pad1p N-terminal) 
domain (6, 7), which will have impact on Cullin-Ring Ligases (CRL) (8, 9). CSN5 has a 
MPN domain containing JAMM (JAB1/MPN/Mov34) or MPN+ motif linked to the 
metalloprotease motif (EXnHXHX10D) that can deneddylate Cullin (9), a process 
important for regulating CRL activity. By comparison, CSN6 is not recognized to have 
JAMM motif and thus its function remain obscure. 
 
1.2. Constitutive Photomorphogenic 1 (COP1), an E3 ubiquitin ligase 
   Mammalian Constitutive Photomorphogenic 1 (COP1) is an evolutionarily conserved E3 
ubiquitin ligase containing RING-finger, coiled-coil, and WD40-repeat domains (10). 
Through association with the COP9 signalosome, COP1 has been identified as a crucial 
mediator to block photomorphogenesis in the dark through the ubiquitinated proteasomal 
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degradation of light-induced transcription factor HY5 (11)(12). In mammalian cells, the 
ubiquitinated targets of COP1 include stress-responsive transcription factors p53 (13) 
and c-JUN (14-16), as well as acetyl-coA carboxylase (17), transducer of regulated 
CREB activity 2 (TORC2, a glucose metabolite regulator) (18) and nucleosome 
remodeling factor MTA1 (19). COP1 is overexpressed in cancers, but whether COP1 
targets any tumor suppressor protein for degradation during tumorigenesis remains 
elusive.  
 
1.3. 14-3-3σ, a tumor suppressor gene 
   The 14-3-3 proteins are a family of evolutionarily conserved regulatory chaperone 
molecules involved in many diverse physiological functions, including signal transduction, 
stress response, apoptosis and cell cycle checkpoint regulation (20, 21). In mammals, the 
14-3-3 family comprises seven isoforms β, ε, γ, ζ, η, σ and τ, which are widely expressed 
in various tissues and exert their biological functions by directly binding to 
phosphoproteins containing the consensus motifs RX(Y/F)XpSXP or RSXpSXP (22). 
Binding by 14-3-3 proteins mediates stability and/or subcellular localization of target 
proteins (23). 14-3-3σ (also known as Stratifin) was originally characterized as a human 
mammary epithelial-specific marker (HME1) (24), and was later found to be an essential 
regulator of apoptosis, cell migration, cell cycle (20, 25) and DNA damage response 
involving p53 and MDM2 (26-28). In contrast to the other 14-3-3 family members, which 
are able to form both homo- and heterodimers, 14-3-3σ can form only homodimers (29). 
This unique characteristic implies that 14-3-3σ has exclusive functions and behaviors. 14-
3-3σ, but not other family members, has been found to be frequently lost or decreased in 
various human cancers (30)(28) and functions as a potential tumor suppressor. In 
response to DNA damage, 14-3-3σ is known to be a p53 downstream target and may 
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serve as a regulator to prevent oxidative and DNA-damage stress-induced mitotic 
checkpoint dysfunction (25, 28). 14-3-3σ also acts as an negative regulator of Akt (31).  
As for its role in cancer, a previous report showed that there is a high frequency of 
hypermethylation at the 14-3-3σ gene locus in breast cancer (32). Posttranscriptional 
regulation such as ubiquitination also regulates 14-3-3σ (33).  Although 14-3-3σ may play 
an important role in protecting cells from DNA damage or cancer, the detailed mechanism 
by which 14-3-3σ is modulated remains not well characterized. 
 
   In this study, we found that CSN6, COP1 and 14-3-3σ interact and we investigated the 
role of the CSN6-COP1 axis in regulating 14-3-3σ stability. Additionally, we found that 
CSN6 induced 14-3-3σ downregulation by enhancing 14-3-3σ ubiquitination, which was 
abrogated when COP1 is knocked down. Further investigation of the underlying 
mechanism revealed that CSN6 physically interacts with COP1 and reduces COP1-
mediated self-ubiquitination, thereby stabilizing COP1.  This in turn reduces COP1-
mediated 14-3-3σ ubiquitination. We previously showed that 14-3-3σ is a negative 
regulator of Akt (31). Subsequently, CSN6 potentiates Akt-mediated FOXO inactivation, 
which results in the transcriptional change of targets regulated by FOXO, thereby 
facilitating cell survival. These data provide insight into how CSN6 overexpression can 
lead to cell growth, transformation, and promote tumorigenicity. Taken together, our 
studies indicate the applicability of employing CSN6-COP1 axis as a therapeutic 
intervention target in cancers.  
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CHAPTER 2. STATEMENT OF OBJECTIVES 
    
Aim 1 : Determine the mechanism of CSN6 mediated 14-3-3σ degradation 
   Our preliminary results show that CSN6 decreases levels of 14-3-3σ. Since CSN6, as 
part of the COP9 signalosome complex, is known to aid E3 ligases in ubiquitination of 
target proteins, ubiquitination of 14-3-3σ is the most likely mechanism. Therefore, I shall 
investigate whether CSN6 increases the ubiquitination of 14-3-3σ. To further clarify the 
mechanism by which CSN6 regulates 14-3-3σ, I shall identify the E3 ligase(s) involved in 
this process.   
 
Aim 2 : Determine the role of CSN6 in the regulation of 14-3-3σtarget proteins 
   14-3-3σ has several down stream effects which include inhibition of Akt. The role of 
CSN6 in how 14-3-3σ regulates this effect can be determined by changing CSN6 
expression in the presence or absence of 14-3-3σ.   
 
Aim 3 : Determine the biological significance of CSN6-mediated 14-3-3 σ 
degradation  
   Our unpublished data indicate that overexpression of CSN6 increases cell proliferation 
and promotes tumor growth. Since CSN6 downregulates and thus antagonizes the 
activity of 14-3-3σ, I will determine the impact of 14-3-3σ on CSN6-mediated cell 
proliferation and tumor promotion.  
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CHAPTER 3. MATERIALS AND METHODS 
 
3.1. Cell culture and reagents 
   HCT116 p53 −/− cells were provided by Dr. Bert Vogelstein. Human 293T were cultured 
in DMEM/F12 medium supplemented with 10% fetal bovine serum, 100 units/ml penicillin 
G, 100 µg/mlstreptomycin and 0.25 µg/ml amphotericin B. HCT116 cells and U2OS cells 
were maintained in McCoy’s 5A medium supplemented with fetal bovine serum and 
antimicrobials as mentioned above. For transient transfections, cells were transfected 
with DNA using either (Lipofectamine 2000 (Invitrogen), or FuGENE HD (Roche) 
reagents according to protocols of the manufacturers. Antibodies to the following epitopes 
and proteins were purchased from the indicated vendors: Flag (M2 monoclonal antibody, 
Sigma), Tubulin (Sigma), COP1 (Bethyl Laboratories), CSN6 (Biomol), 14-3-3σ (RDI), 
Myc (mouse monoclonal 9E10, Santa Cruz Biotechnology), pAkt (Cell Signaling 
Technology), Akt (Cell Signaling Technology), PARP (Cell Signaling Technology), HA 
(12CA5, Roche) and Actin (Sigma).  
 
3.2. Plasmids 
   pcDNA6-Myc-CSN6 and pcDNA6-Myc-COP1 were constructed in our lab by PCR. 
pCMV5-Flag-14-3-3σ, Ad-β-gal, and Ad-14-3-3σ was previously described (26). Flag-
CSN6 (wt), 1-184 aa and 185-327 aa as well as Flag-14-3-3σ (wt), 1-161 aa and 153-248 
aa were generated using standard PCR cloning methods. HA-Akt and DN-Akt were 
previously described (31). FOXO luciferase reporter gene was used as described (47). 
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3.3. Immunoprecipitation and immunoblotting  
   Total cell lysates were solubilized in lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1 
mM EDTA, 0.5% Nonidet P-40, 0.5% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 1 
mM sodium fluoride, 5 mM sodium orthovanadate and 1 µg/ml each of aprotinin, 
leupeptin, and pepstatin) and processed as previously described (20). Lysates were 
immunoprecipitated with indicated antibodies according to standard protocols. Proteins 
were resolved by SDS-PAGE gel and proteins transferred to polyvinylidene difluoride 
membranes (Millipore). Membranes were blocked with 5% nonfat milk for 1 hr at room 
temperature prior to incubation with indicated primary antibodies. Subsequently, 
membranes were washed and incubated for 1 hr at room temperature with peroxidase-
conjugated secondary antibodies (Thermo Scientific). Following several washes, 
chemiluminescent images of immunodetected bands on the membranes were recorded 
on X-ray film using the enhanced chemiluminescence (ECL) system (Roche).  
 
3.4. In vitro binding assay  
   Flag-CSN6 and myc-COP1 were prepared by in vitro transcription and translation using 
the TNT coupled system as previously described (Promega)(20). TNT Proteins were 
mixed and immunoprecipitated with anti-Myc followed by immunoblotting with anti-Flag 
as described. 
 
3.5. In vivo ubiquitination assay  
   HCT116 and U2OS cells were used to detect endogenous COP1 and 14-3-3σ   
ubiquitination.  293T cells were transiently co-transfected with indicated plasmids to 
detect exogenous 14-3-3σ ubiquitination. Forty-eight hours later, cells were treated with 5 
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µg/mL MG132 (Sigma) for 6 hr. Cells were harvested and lysed with lysis buffer (50 mM 
Tris pH 7.5, 150 mM NaCl, 0.5% NP-40, 0.5% Triton X-100 and 5 mM NEM). 
Ubiquitinated COP1 was immunoprecipitated with anti-COP1 (Santa Cruz Biotechnology, 
Inc.) and immunoblotted with anti-HA (Roche). Ubiquitinated 14-3-3σ was 
immunoprecipitated with Flag (M2 monoclonal antibody, Sigma) or anti-14-3-3σ (RDI) and 
immunoblotted with anti-HA (Roche). Protein complexes were then resolved by 10% 
SDS-PAGE to allow observation of the polyubiquitinated COP1 or 14-3-3σ.  
 
3.6. In vitro Ubiquitination Assay 
   For detection of ubiquitinated 14-3-3σ in vitro, purified 14-3-3σ proteins were incubated 
with different combinations of ubiquitin (200 pmol), E1 (2 pmol), E2-UbcH5a/5b (10 pmol), 
in vitro translated COP1 and ATP (2 mM) in a total volume of 50 ìl for 1 h at 37oC. 
Reaction products were resolved with 8% SDS-polyacrylamide gels and probed with anti-
14-3-3σ or anti-GST. His-Ubiquitin (UW 8610), E1 (UW 9410) and E2 (UW 9050) were 
purchased from BioMol International.  
 
3.7. Cell lysates fractionated by Gel filtration  
   HCT116 and U2OS cell lysates were fractionated through Superose 6 column 
(GEHealthcare) equilibrated with lysis buffer at a flow rate of 0.3ml/min. Fractions of 
300μl each were collected and subjected to immunoblot. 
 
3.8. Quantitative PCR  
   Primers for real-time quantitative PCR of CSN6 (5’-GCACAGACAAGTTCAAGA; 5’- 
GTGATGGTGCCGAGGTAG), COP1 (5’- CTGCAACGGGCTCATCAACT; 5’- 
GGCCACATTTTGTCATGTATGCT), 14-3-3σ (5’-CTCTCCTGCGAAGAGCGAAAC; 5’-
  
8 
CCTCGTTGCTTTTCTGCTCAA) 14-3-3σ target genes— BTG (5’-
CGACAGCTGCAGACCTTCAG; 5’-GGTTGATGCGAATACAACGGTA), FOXO1 (5’-
GTCAAGAGCGTGCCCTACTTC; 5’-CTTGCCACCCTCTGGATTGAG), BCL6 (5’-
AGCCCATAAAACGGTCCTCAT; 5’-GAGGATGCAGAATCCCTCAG), BCLxL (5’-
AAGCGGTCCCGTGGATAGA; 5’-TCCGGTATTCGCAGAAGTCC) and GAPDH (5’-
AAGGTGAAGGTCGGAGTCAAC; 5’-GAGTTAAAAGCAGCCCTGGTG) were as 
referenced in Primer Bank (http://pga.mgh.harvard.edu/primerbank/). Quantitative PCR 
amplification of GAPDH was used for normalization. Total RNAs were extracted from cells 
using Trizol (Invitrogen); 1 µg RNA was used for producing cDNA by iScript cDNA 
Synthesis Kit (Bio-Rad). Quantitative real-time PCR analyses were performed using iQ 
SYBR Green Super mix (Bio-Rad, 170-8882) and the iCycler iQ Real-time PCR detection 
system.  
 
3.9. Luciferase assay 
   A FOXO luciferase reporter gene containing a FOXO transcription factor binding site 
was co-transfected with the pCMV-Myc-CSN6, pCMV-Flag-14-3-3σ or DN-Akt expressing 
vectors into 293T or HCT116 cells. Luciferase activity was assayed with the dual 
luciferase assay system (Promega) according to the manufacturer’s instructions. 
 
3.10. FACS Analysis for apoptosis assay 
   Apoptosis was determined by two-color analysis using propidium iodide (PI) and FITC-
conjugated anti-Annexin V (BD Pharmingen, USA) according to the manufacturer’s 
instructions. Cells were harvested and washed three times with PBS then cells were 
stained with PI and FITC-conjugated anti-Annexin V and analyzed with a FACScalibur 
flow cytometer. 
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3.11. Generation of stable transfectants 
   For generation of Myc-CSN6 overexpression stable transfectants, HCT116 and U2OS 
cells were transfected with either PCDNA6 or PCDNA6-Myc-CSN6 plasmids by 
electroporation (Amaxa). Forty-eight hours later, cells were selected in 8µg/ml Blasticidin 
containing culture medium for 2 weeks. For generation of CSN6 knock-down stable cell 
lines, HCT116 and U2OS cells were infected by lentiviral shRNA transduction particles 
(Sigma, NM_006833 COPS6 MISSION shRNA lentiviral transduction particles) containing 
either control shRNA or CSN6 shRNA. After infection, cells were selected with 2µg/ml 
Puromycin for two weeks.  
 
3.12. Soft agar colony formation 
   10,000 cells were mixed in 0.35% agarose/complete media were plated on 0.7% 
agarose/complete media (bottom) layer and grown for 8 weeks. Colonies were stained 
with 0.5 mg/ml p-iodonitrotetrazolium violet (Sigma) and were counted under a light 
microscope (Olympus IX70). Each experiment was done at least two times in triplicate 
wells. 
 
3.13. Foci formation 
   1000, 2000 or 3000 cells were plated in 6-well plates and then incubated for 7−10 days. 
Cells were stained with 0.005% crystal violet to visualize the colonies growing in each 
well. 
 
3.14. MTT assay 
   Vector control or CSN6-expressing cells were infected with Ad-β-gal (MOI = 100) or Ad-
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HA-14-3-3σ (MOI =100). Cells were plated at 3000 cells/well in 96-well plates and grew in 
the continued presence of selective antibiotics. Cells were counted every day using a 
colorimetric 5 mg/ml MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
for 3 hrs. Following MTT incubation, cells were lysed in 200 µL of 100% DMSO (Fisher). 
Samples were then analyzed using a spectrophotomer to measure the optical density at 
570 nm. 
 
3.15. Xenograft experiment  
   Four to six week-old female athymic (nu/nu) mice (Experimental Radiation Oncology, M. 
D. Anderson Cancer Center, Houston, TX, USA) were housed in AAALAC-approved 
barrier facilities with food and water ad libitum and maintained in the animal facility at The 
University of Texas M. D. Anderson Cancer Center. Mice were divided into different 
groups. CSN6-expressing cells infected with Ad-β-gal (MOI = 100) or Ad-14-3-3σ (MOI 
=100) were harvested and injected into the flank of each mouse. Tumor volumes were 
measured and recorded from day 8 after injection. At the end of the experiment, the mice 
were euthanized with CO2 and the tumors were removed and weighed. 
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CHAPTER 4. RESULTS 
 
4.1. CSN6 associates with 14-3-3σ  
 
   Others have characterized proteins that associate with the CSN complex (34)(35), and 
many more remain to be identified. In Fig. 3A we show that CSN6 and 14-3-3σ coelute by 
gel filtration. This led us to the hypothesis that 14-3-3σ and CSN6 may associate in 
complex. Coimmunoprecipitation experiments. indeed shows their in vivo interaction (Fig. 
1). We then mapped CSN6 binding region on14-3-3σ. The results showed that CSN6 
binds to the C-terminus of 14-3-3σ (aa 153-248), but not the N-terminus (aa 1-161 
containing dimerization domain) (Fig. 2). We also mapped 14-3-3σ binding region on 
CSN6 in vitro. A GST-pull-down assay suggests that the N-terminus of CSN6 was 
responsible for binding 14-3-3σ. (Fig. 3). These results demonstrate that the N-terminal 
region of CSN6 binds to the C-terminal region of 14-3-3σ. 
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Figure 1. CSN6 interacts with 14-3-3σ in vivo. 
 
Interaction of endogenous CSN6 with endogenous 14-3-3σ. Lysates of HCT116 cells 
were prepared and equal amounts of cell lysates were immunoprecipitated with indicated 
antibodies followed by immunoblotting with indicated antbibodies. 
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Figure 2. Mapping of 14-3-3σ domain interaction with CSN6.   
 
Mapping of CSN6 binding domains on 14-3-3σ. Myc-CSN6 and Flag-14-3-3σ (aa 1-248), 
N-terminus (aa 1-161) or C-terminus (aa 153-248) was co-transfected into 293T cells. 
Cell lysates were immunoprecipitated with anti-Flag and immunoblotted with anti-Myc.  
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                                                                                   Figure 2 
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Figure 3. Mapping of the 14-3-3σ binding region within CSN6.   
 
Mapping of 14-3-3σ binding domains on CSN6. Flag-CSN6 (aa 1-327), N-terminal (aa 1-
184) or C-terminal (aa 185-327) were transfected into 293T cells. Cell lysates were 
subjected to GST-14-3-3σ pull-down (PD) and immunoblotted with anti-Flag antibody. 
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                                                                                   Figure 3 
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4.2. CSN6 negatively regulates 14-3-3σ protein stability  
 
4.2.1 CSN6 down-regulates 14-3-3σ at the post-transcriptional level 
   Because CSN6 interacts with 14-3-3σ, we reasoned that CSN6 has some biological 
impact on 14-3-3σ. The 14-3-3σ levels were elevated when cells were infected with 
CSN6-shRNA virus to perform CSN6 knockdown (Fig. 4A, left). Exogenous expression of 
CSN6 also downregulated 14-3-3 σ expression (Fig. 4A, right) in a dose-dependent 
manner (Fig. 4B). CSN6-mediated 14-3-3σ downregulation was suppressed by MG132, a 
proteasome inhibitor, suggesting the involvement of 26S proteasome. (Fig. 5). The mRNA 
levels of 14-3-3σ were not affected by CSN6 overexpression or knockdown in a real-time 
quantitative PCR analysis (Fig. 6), suggesting that CSN6 downregulates 14-3-3σ at the 
post-transcriptional level. 
 
4.2.2 CSN6 increases 14-3-3σ polyubiquitination 
   To investigate if CSN6 can destabilize 14-3-3σ at the protein level we performed a 
turnover rate experiment. Indeed, CSN6 knockdown can reduce the turnover rate of 14-3-
3σ in the presence of the de novo protein synthesis inhibitor, cycloheximide (Fig. 7A). 
Consistently, overexpression of CSN6 increases turnover rate of 14-3-3σ (Fig. 7B). 
Further, we found that CSN6 increased the endogenous ubiquitination level of 14-3-3σ 
(while CSN6 knockdown reduced the endogenous ubiquitination level of 14-3-3σ (Fig. 8 
top). Also, increasing amounts of CSN6 shRNA antagonized poly-ubiquitination of 
transfected 14-3-3σ in a dose-dependent manner (Fig. 8 bottom).   
 
4.2.3 Downregulation of 14-3-3σ by CSN6 is not dependent on p53  expression  
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   Since 14-3-3σ is regulated by p53 (25), at issue is whether CSN6-mediated 14-3-3σ 
downregulation involves p53. We compared 14-3-3σ protein levels in HCT116 p53 -/- 
cells infected with CSN6 shRNA virus or control shRNA virus and found that 14-3-3σ 
protein levels were still higher in HCT116 p53 -/- cells knocked down for CSN6 versus 
control virus (Fig. 9). This result suggests that downregulation of 14-3-3σ by CSN6 is not 
dependent on p53 expression. 
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Figure 4. CSN6 reduces the steady-state expression levels of 14-3-3σ.  
 
A. 14-3-3σ protein level is upregulated when endogenous CSN6 expression is inhibited 
with shRNA (left). Lysates of HCT116 cells infected with either CSN6 shRNA or control 
shRNA were immunoblotted with anti-14-3-3σ, CSN6 or Actin antibodies. 14-3-3σ protein 
level was downregulated in CSN6 overexpressing cells (right). Lysates of Myc-CSN6 
overexpressing HCT116 stable transfectants and vector control transfectants were 
immunoblotted with anti-14-3-3σ, CSN6, or Actin antibodies.  
 
B. Ectopic expression of CSN6 reduces 14-3-3σ expression. 293T cells were co-
transfected with the indicated expression vectors. Equal amounts of protein from cell 
lysates were immunoblotted with anti-Flag, Myc, or Actin antibodies. 
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                                                                                   Figure 4 
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Figure 5. CSN6 down-regulates 14-3-3σ through 26S proteasome pathway.    
 
293T cells were co-transfected with the indicated plasmids. Cells were treated with or 
without proteasome inhibitor MG132 before collecting lysates. Lysates were 
immunoblotted with anti-Flag or Tubulin antibodies. 
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                                                                                   Figure 5 
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Figure 6. CSN6 down-regulates 14-3-3σ at the post-transcriptional level.  
  
A. mRNA levels of 14-3-3σ are not affected by overexpression of CSN6. Real-time 
quantitative PCR analysis of 14-3-3σ in 293T cells transfected with or without Myc-CSN6 
showed no obvious difference in 14-3-3σ mRNA levels. 
 
B. mRNA levels of 14-3-3σ are not affected by knockdown of CSN6 expression. Real-
time quantitative PCR analysis of 14-3-3σ in HCT116 cells infected with CSN6 shRNA or 
control shRNA showed no obvious difference in 14-3-3σ mRNA levels. 
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Figure 7. CSN6 increases 14-3-3σ turnover rate.    
 
A. HCT116 cells infected with either lentiviral CSN6 shRNA or control shRNA were 
treated with cycloheximide (CHX) (100 µg/ml) for the indicated times. Cell lysates were 
immunoblotted with anti-14-3-3σ, CSN6, or Actin antibodies. Integrated OD values of 
bands at each time point were measured using a densitometer. Levels of 14-3-3σ at time 
zero were set at 100%. Remaining 14-3-3σ is indicated graphically (right). 
  
B. 293T cells were co-transfected with the indicated expression vectors. Forty-eight hours 
after transfection, the cells were treated with cycloheximide (CHX) (100 µg/ml) for the 
indicated times. Cell lysates were immunoblotted with anti-Flag, Myc, or Actin antibodies. 
Integrated OD values of bands at each time point were measured using a densitometer.  
Levels of 14-3-3σ at time zero were set at 100%. 14-3-3σ remaining is indicated 
graphically.  
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                                                                                   Figure 7 
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Figure 8. CSN6 increases 14-3-3σ poly-ubiquitination.    
 
CSN6 increases endogenous 14-3-3σ polyubiquitination (top). Indicated or transfected 
cells were treated with MG132 for four hours before harvesting.  Polyubiquitinated 14-3-
3σ was immunoprecipitated with anti-14-3-3σ and immunoblotted with anti-HA. Equal 
amounts of cell lysates were immunoblotted with anti-CSN6 or Actin.  
 
Knockdown of CSN6 reduces poly-ubiquitination of exogenous 14-3-3σ (bottom). 293T 
cells were co-transfected with indicated plasmids and increasing amounts of CSN6 
shRNA. Cells were treated with MG132 for four hours before harvesting.  
Polyubiquitinated 14-3-3σ was immunoprecipitated with anti-Flag and immunoblotted with 
anti-HA. Equal amounts of cell lysates were immunoblotted with anti-CSN6 or Actin 
antibodies. 
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                                                                                   Figure 8 
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Figure 9. Downregulation of 14-3-3σ by CSN6 is not dependent on p53 expression.  
 
HCT116 p53 -/- cells were infected with either CSN6 shRNA or luciferase shRNA. Equal 
amounts of cell lysates were immunoblotted with anti-14-3-3σ, CSN6, or Actin antibodies. 
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                                                                                   Figure 9 
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4.3. CSN6 regulates 14-3-3σ protein stability through E3 ubiquitin ligase COP1 
 
4.3.1 Gel filtration and elution profiles analysis of CSN6, COP1 and 14-3-3σ  
   The COP9 signalosome (CSN) and COP1 are required for the dark-dependent 
degradation of the transcription factor HY5 (12), a positive regulator of 
photomorphogenesis in plants.  Although CSN is required for proper functioning of COP1, 
a direct interaction between CSN and COP1 has not been characterized. To investigate 
this possible direct interaction, we analyzed HCT116 and U2OS cell lysates separated 
with gel filtration columns. Lysate fractions were analyzed by SDS-PAGE and 
immunoblotting. Fig. 10 shows that COP1, CSN6, and 14-3-3σ are present in the 
fractions corresponding to the molecular size of the COP9 holocomplex (between 400-
693 kDa), suggesting the interaction of COP1 and 14-3-3σ with the COP9 signalosome. 
These observations led us to investigate the functional relevance of the interaction of 
CSN6 and COP1.   
 
4.3.2 CSN6 interacts with COP1 and elevates the steady-state protein levels of COP1 at 
the post-transcriptional level 
   Fig. 11 shows that CSN6 associates with COP1 endogenously as assayed by co-ip and 
an In vitro binding assay confirms that CSN6 directly binds to COP1. To address the 
significance of the CSN6 and COP1 interaction, we examined the impact of CSN6 on 
COP1 levels and noted that the steady-state level of COP1 increased when CSN6 was 
overexpressed (Fig. 12A). The mRNA levels of COP1 were not affected by CSN6 
expression in a real-time quantitative PCR analysis (Fig. 12B), suggesting that CSN6 up-
regulates COP1 at the post-transcriptional level.   
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4.3.3 CSN6 reduces poly-ubiquitination of COP1 
   Further, the turnover rate of endogenous COP1 was reduced in CSN6 overexpressing 
cells in a cycloheximide chase assay (Fig. 13). We also examined the effect of CSN6 on 
COP1 ubiquitination. As expected, polyubiquitinated COP1 was reduced in CSN6 
overexpressing cells compared with control cells (Fig. 14). Taken together, these findings 
demonstrate that CSN6 increases COP1 stability through inhibition of ubiquitin-mediated 
COP1 proteasomal degradation.  
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Figure 10. Gel filtration and elution profiles analysis of CSN6, COP1 and 14-3-3σ.  
 
The distributions of CSN6, 14-3-3σ, and COP1 were analyzed by gel filtration 
chromatography. Immunoblots of the fractions for indicated proteins are shown in both 
HCT116 (A) and U2OS (B) cells. Molecular weight markers are indicated.  
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                                                                                 Figure 10 
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Figure 11. CSN6 interacts with COP1. 
 
A. Endogenous COP1 interacts with endogenous CSN6. Lysates of U2OS cells were 
prepared and equal amounts of cell lysates immunoprecipitated with either  rabbit IgG or 
anti-COP1 antibodies followed by immunoblotting with anti-CSN6 antibody (left panel).   
 
B. COP1 is shown to interact with CSN6 in vitro (right panels). Myc-COP1 and Flag-
CSN6 cDNAs were transcribed and translated in vitro. COP1 and CSN6 proteins were 
incubated overnight and immunoprecipitated with anti-Myc followed by immunoblotting 
with anti-Flag.  
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                                                                                  Figure 11 
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Figure 12. Overexpression of CSN6 elevates the steady-state protein levels of 
COP1 at the post-transcriptional level. 
 
A. Lysates of Myc-CSN6 overexpressing U2OS stable transfectants or vector control 
transfectants were immunoblotted with anti-COP1, CSN6, or Actin antibodies.   
 
B. mRNA levels of COP1 are not affected by overexpression of CSN6. Real-time 
quantitative PCR analysis of COP1 in Myc-CSN6 overexpressing U2OS stable 
transfectants or vector control transfectants showed no obvious difference in COP1 
mRNA levels. 
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Figure 13. CSN6 decreases COP1 turnover rate.  
 
Myc-CSN6 overexpressing U2OS stable transfectants and vector control transfectants 
were treated with cycloheximide (CHX) (100 µg/ml) for indicated times. Cell lysates were 
immunoblotted with anti-COP1, Myc, or Actin antibodies. Integrated OD values of bands 
at each time point were measured using a densitometer. Levels of COP1 at time zero 
wwere set at 100%. COP1 remaining is indicated graphically. 
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Figure 14. CSN6 reduces poly-ubiquitination of COP1.   
 
Myc-CSN6 overexpressing U2OS stable transfectants or vector control transfectants 
were transfected with HA-Ubiquitin. Cells were treated with MG132 four hours before 
harvesting. Polyubiquitinated COP1 was immunoprecipitated with anti-COP1 and 
immunoblotted with anti-HA antibodies. Equal amounts of cell lysates were 
immunoblotted with anti-CSN6 or Actin antibodies. 
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                                                                                 Figure 14 
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4.4. COP1 is required for CSN6-mediated 14-3-3σ degradation 
 
4.4.1 COP1 interacts with 14-3-3σ and Knockdown of COP1 expression reduces poly-
ubiquitination of 14-3-3σ 
   Given that CSN6 associates with COP1 and that COP1 coelutes with 14-3-3σ in gel 
filtration assays (Fig. 10), we reasoned that COP1 could be involved in CSN6-mediated 
14-3-3σ ubiquitination. Indeed, 14-3-3σ was able to associate with COP1 endogenously 
as assayed by co-ip (Fig. 15). Increasing amounts of COP1 shRNA also increased 
steady-state levels of 14-3-3σ (Fig. 16A). Consistently, COP1 shRNA reduced the 
turnover rate of 14-3-3σ in 293T cells (Fig. 17) and COP1 shRNA reduced 
polyubiquitinated 14-3-3σ levels in a dose-dependent manner (Fig. 18). 
 
4.4.2 Knockdown of COP1 expression in CSN6 overexpressing cells increases 14-3-3σ 
expression through reducing CSN6-mediated poly-ubiquitination of 14-3-3σ 
   COP1 shRNA also increased endogenous levels of 14-3-3σ in HCT116 cells (Fig. 16B) 
and the mRNA levels of 14-3-3σ were not significantly affected by COP1 shRNA, 
suggesting that COP1 shRNA upregulates 14-3-3σ at the post-transcriptional level (Fig. 
16C). In light of the observation that CSN6 stabilized COP1 and negatively regulated 14-
3-3σ, we further evaluated the impact of COP1 on CSN6-mediated 14-3-3σ poly-
ubiquitination. We found that increasing amounts of COP1 shRNA in HCT116 cells 
overexpressing CSN6 led to increased 14-3-3σ steady-state expression (Fig. 19A). 
Levels of CSN6-mediated 14-3-3σ poly-ubiquitination were also compromised by 
increasing amounts of COP1 shRNA (Fig. 19B).   
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4.4.3 COP1 induces the ubiquitination of 14-3-3σ in an in vitro ubiquitination assay   
   As expected, COP1 also efficiently increased the ubiquitination level of 14-3-3σ in an in 
vitro ubiquitination assay (Fig. 20). These results suggested that COP1 is a novel E3 
ligase for 14-3-3σ whose ubiquitination is also mediated by CSN6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
46 
 
Figure 15. COP1 interacts with 14-3-3σ in vivo. 
 
Endogenous COP1 interacts with endogenous 14-3-3σ. Lysates of HCT116 cells were 
prepared and equal amounts of cell lysates immunoprecipitated with either mouse IgG or 
14-3-3σ followed by immunoblotting with anti-COP1 antibody.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
47 
 
                                                                                 Figure 15 
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Figure 16. Knockdown of COP1 expression elevates the steady-state levels of 14-3-
3σ at the post-transcriptional level. 
 
A. 14-3-3σ protein level is upregulated when endogenous COP1 expression is inhibited 
with shRNA. 293T cells were co-transfected with indicated plasmids and increasing 
amounts of COP1 shRNA. Equal amounts of cell lysates were immunoblotted with anti-
Flag, COP1, or Actin antibodies. 
 
B. 14-3-3σ protein level was upregulated when endogenous CSN6 expression was 
inhibited by shRNA. Lysates of HCT116 cells transfected with increasing amounts of 
CSN6 shRNA were immunoblotted with anti-14-3-3σ, COP1, or Actin antibodies.   
 
C. mRNA levels of 14-3-3σ are not significantly affected by knockdown of COP1 
expression. Real-time quantitative PCR analysis of 14-3-3σ in HCT116 cells transfected 
with COP1 shRNA or control shRNA showed no significant difference in 14-3-3σ mRNA 
levels. 
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                                                                                 Figure 16 
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Figure 17. Knockdown of COP1 expression reduces 14-3-3σ turnover rate.   
 
293T cells were transfected with the indicated expression vectors. Forty-eight hours after 
transfection, the cells were treated with cycloheximide (CHX) (100 µg/ml) for the 
indicated times. Cell lysates were immunoblotted with anti-Flag, COP1, or Actin 
antibodies. Integrated OD values of bands at each time point were measured using a 
densitometer. The level of 14-3-3σ at time zero was set at 100%. 14-3-3σ remaining is 
indicated graphically.  
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Figure 18. Knockdown of COP1 expression reduces poly-ubiquitination of 14-3-3σ.  
 
293T cells were co-transfected with indicated plasmids and increasing amounts of COP1 
shRNA. Cells were treated with MG132 four hours before harvest, and polyubiquitinated 
14-3-3σ immunoprecipitated with anti-Flag followed by immunoblotting with anti-HA. 
Equal amounts of cell lysates were immunoblotted with anti-COP1 or Actin antibodies. 
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                                                                                 Figure 18 
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Figure 19. Knockdown of COP1 expression in CSN6 overexpressing cells 
increases 14-3-3σ expression through reducing CSN6-mediated poly-ubiquitination 
of 14-3-3σ. 
 
A. Knockdown of COP1 expression in CSN6 overexpressing cells increases the steady-
state expression of 14-3-3σ. Lysates of Myc-CSN6 overexpressing HCT116 cells 
transfected with increasing amounts of COP1 shRNA were immunoblotted with anti-14-3-
3σ, COP1, or Actin antibodies.   
 
B. Knockdown of COP1 expression in CSN6 overexpressing cells reduced the poly-
ubiquitination of 14-3-3σ. Myc-CSN6 overexpressing HCT116 cells were co-transfected 
with indicated plasmids and increasing amounts of COP1 shRNA. Cells were treated with 
MG132 four hours before harvest. Polyubiquitinated 14-3-3σ was immunoprecipitated 
with anti-14-3-3σ and immunoblotted with anti-HA antibodies. Equal amounts of cell 
lysates were immunoblotted with anti-COP1 or Actin antibodies. 
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Figure 20. COP1 induces the ubiquitination of 14-3-3σ in an in vitro ubiquitination 
assay.   
 
GST-14-3-3σ was incubated with or without Myc-COP1 which was prepared with in vitro 
translation (TNT) in the presence of E1, E2, His-Ubiquitin and ATP as indicated. 
Ubiquitinated 14-3-3σ  was detected by immunoblotting with anti-14-3-3σ or anti-GST 
antibodies. 
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                                                                                 Figure 20 
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4.5. CSN6-14-3-3σ axis regulates Akt-mediated cell survival and FOXO 
transcriptional activity  
 
4.5.1 CSN6 has impact on Akt activity 
   Akt has been implicated in the control of cell survival. For example, mice with targeted 
disruption of the akt1 gene are more sensitive to apoptosis-inducing stimuli (36). Because 
14-3-3σ suppresses Akt activity (31), we first examined whether knockdown of CSN6 
could suppress Akt activity and inhibit Akt-mediated cell survival. To address this, we 
used U2OS cells infected with CSN6 shRNA virus or control virus and found that Akt 
activity was suppressed when CSN6 was knocked down versus control (Fig. 21A) as 
indicated by reduced phosphorylation of Akt at Serine 473. In order to determine whether 
lower Akt activity in CSN6 knockdown cells leads to apoptosis, cells were analyzed for 
Annexin V staining at day 4 after serum starvation. Knockdown of CSN6 demonstrated 
significant increases in both early apoptotic (Annexin V staining 41.9%, at right bottom 
quadrant) and late apoptotic cells (Annexin V staining 13.6% at right upper quadrant) 
compared to control cells (18.0% and 5.4%, respectively) (Fig. 21B). Cells were also co-
transfected with constitutively active Akt (HA tagged-Akt) or treated with LY294002 (PI3K 
inhibitor). As expected, LY294002 have added the impact on shCSN6-mediated 
apoptosis in the absence of serum (Fig. 21B). In contrast, the exogenous HA tagged-Akt 
prevented the potentiation of CSN6 shRNA in serum starvation-mediated cell death (Fig. 
21B), suggesting that the CSN6-Akt axis is involved in cell survival. Also, cells were 
serum starved and analyzed for the presence of the cleaved form of PARP, an apoptosis 
marker. CSN6 knockdown cells showed more PARP cleavage compared with control 
cells (Fig. 21C). Taken together, these results suggest that knockdown of CSN6 resulted 
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in enhanced apoptotic cell death when the cells were cultured in serum free medium and 
that loss of cell viability was likely to be due to the suppression of Akt activity.  
 
4.5.2 CSN6 suppresses FOXO target gene expression 
   Akt has been reported to suppress FOXO transcriptional activity through 
phosphorylation (37, 38). Since CSN6 downregulates 14-3-3σ expression and thus 
enhances Akt activity, we next examined the impact of CSN6 on the Akt-mediated 
suppression of FOXO transcriptional activity. As expected, Akt activity in CSN6 
overexpressing HCT116 cells was higher than in control cells (Fig. 22A). We then 
examined the target gene expression of FOXO transcription factors under the condition of 
CSN6 overexpression. In Fig. 22B we show that FOXO transcriptional targets, such as 
BTG, FOXO1 and BCL6, were decreased in HCT116 CSN6-overexpressing cells (Fig. 
22B). Consistently, BCL-xL, which is repressed by BCL6, was upregulated in CSN6 
overexpressing HCT116 cells reflecting the impact of CSN6-mediated suppression of 
BCL6 (Fig. 22B).   
 
4.5.3 14-3-3σ and DN-Akt antagonizes CSN6-mediated FOXO transcriptional activity  
   To demonstrate the link between CSN6, 14-3-3σ, Akt and FOXO, we analyzed the 
functional link by employing a FOXO-responsive luciferase reporter gene assay. We 
found that CSN6 expression impaired FOXO transcriptional activity (Fig. 23), and this 
effect was reversed by increased expression of Flag-14-3-3σ or DN-Akt (Fig. 23). Taken 
together, overexpression of CSN6 leads to downregulation of 14-3-3σ, which in turn 
activates Akt kinase, resulting in the suppression of FOXO transcriptional activity.       
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Figure 21. CSN6 has impact on Akt activity.  
 
A. Knockdown of CSN6 expression suppresses Akt activity. Lysates of U2OS cells 
infected with either CSN6 shRNA or control shRNA were immunoblotted with anti-
phospho-Akt, Akt, 14-3-3σ, CSN6, or Actin antibodies.   
 
B. Knockdown of CSN6 accelerates apoptosis induced by serum starvation. U2OS cells 
infected with either CSN6 shRNA or control shRNA were transfected with either empty 
vector or HA-Akt. Cells were cultured in 0% FBS containing either DMSO or 10 µM of 
LY294002 (LY) for four days.  Binding of Annexin V and uptake of propidium iodide were 
analyzed by flow cytometry. Left panel, representative analysis of apoptotic cells. The 
lower left quadrant contains the viable population of cells, the lower right quadrant 
contains early apoptotic cells, the upper left quadrant contains necrotic cells and the 
upper right quadrant contains late apoptotic cells.  The mean of three data sets was taken 
and the values shown from the corresponding quadrant (right panel).  
 
C. Knockdown of CSN6 expression leads to PARP cleavage. U2OS cells infected with 
either CSN6 shRNA or control shRNA were cultured in 0% FBS for indicated times. Cell 
lysates were immunoblotted with anti-PARP or anti-Actin antibodies.   
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62 
 
Figure 22. CSN6 suppresses FOXO target gene expression. 
 
A. Overexpression of CSN6 enhances Akt activity. Lysates of Myc-CSN6 overexpressing 
HCT116 stable transfectants or vector control transfectants were immunoblotted with anti-
phospho-Akt, Akt, CSN6, or Actin antibodies.   
 
B. CSN6 suppresses FOXO target gene expression. mRNA levels of the indicated FOXO 
target genes were determined by quantitative RT-PCR in HCT116 cells stably expressing 
either Myc-CSN6 or vector control.  
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Figure 23. 14-3-3σ and DN-Akt antagonizes CSN6-mediated FOXO transcriptional 
repression. 
 
HCT116 (A) and 293T (B) cells were co-transfected with a FOXO-responsive luciferase 
reporter and the indicated expression vectors. Relative luciferase activity is shown as a 
bar graph. 
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                                                                                 Figure 23 
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4.6. CSN6-14-3-3σ axis regulates cell growth and tumorigenicity. 
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4.6.1 14-3-3σ inhibits CSN6-mediated cell proliferation 
   Since CSN6 downregulates and thus antagonizes the activity of 14-3-3σ, we reasoned 
that CSN6 would have a role in cell proliferation and anchorage-independent growth. In 
Fig. 24 we show that indeed CSN6 overexpression facilitates cell growth. Since CSN6 
can mediate 14-3-3σ inhibition, we sought to examine the growth effect of expressing 14-
3-3σ in terms of cell proliferation, foci formation, and anchorage-independence in CSN6-
overexpressing cells.  We found that CSN6 overexpressing HCT116 cells infected with 
Ad-14-3-3σ showed inhibition of cell proliferation, foci formation, and anchorage-
independent growth when compared with the Ad-β-gal control (Fig. 24).  
 
4.6.2 14-3-3σ suppresses tumorigenesis of CSN6-overexpressing cells 
   Our unpublished data indicate that overexpression of CSN6 promotes tumor growth 
(39).  Because 14-3-3σ suppresses CSN6-mediated cell proliferation and anchorage-
independent growth, we next examined the impact of 14-3-3σ on CSN6-mediated tumor 
promotion. We observed that xenografted tumor volume was significantly decreased in 
Ad-14-3-3σ-treated mice compared with Ad-β-gal-treated mice (Fig. 25A). Further, the 
average excised tumor weight per mouse in the Ad-β-gal-treated group (507 mg) was 
higher than in the Ad-14-3-3σ-treated group (310 mg) (Fig. 25B). Tumors obtained from 
this study were fixed, embedded in paraffin, and sections were examined. 
Immunohistochemistry staining indicated that cell proliferation marker, Ki67, was reduced 
in tumors from Ad-14-3-3σ-treated mice when compared with the control group, while the 
signal intensity of apoptotic marker, cleaved Caspase 3, was increased in the Ad-14-3-
3σ-treated group when compared with the Ad-β-gal-treated group (Fig. 25D). Together, 
these data illustrate that the COP9 signalosome subunit 6-14-3-3σ axis is deregulated 
when CSN6 is overexpressed, and this promotes cell growth and tumorigenicity. 
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Significantly, 14-3-3σ expression can correct the abnormalities mediated by CSN6 
expression.  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 24. 14-3-3σ inhibits CSN6-mediated cell proliferation.   
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A. Myc-CSN6 overexpressing HCT116 stable transfectants and vector control 
transfectants were plated in 96-well plates and the number of live cells estimated by MTT 
assay every day for a total of 3 days (left, top panel). Results are expressed as  OD570. 
Myc-CSN6 overexpressing HCT116 cells were infected with Ad-β-gal or Ad-HA-14-3-3σ 
(leftbottom panel). Error bars represent 95% confidence intervals. 14-3-3σ antagonizes 
CSN6-mediated foci formation.   
 
B. Myc-CSN6 overexpressing HCT116 stable transfectants and vector control 
transfectants were analyzed for foci formation (Middle, top). Myc-CSN6 overexpressing 
HCT116 cells infected with Ad-β-gal or Ad-HA-14-3-3σ were plated at low density and 
allowed to form foci (middle, bottom).   
 
C. Myc-CSN6 overexpressing HCT116 stable transfectants, vector control transfectants 
or Myc-CSN6 overexpressing HCT116 cells infected with Ad-β-gal or Ad-HA-14-3-3σ 
were analyzed for soft agar colony formation (right, top). Average numbers of colonies 
per field were scored.  Error bars represent 95% confidence intervals. 
 
 
 
 
 
 
 
                                                                                 Figure 24 
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Figure 25. 14-3-3σ suppresses tumorigenesis of CSN6-overexpressing cells.   
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A. Myc-CSN6 overexpressing HCT116 stable transfectants were infected with Ad-14-3-3σ 
or Ad-β-gal. Cells were harvested and subcutaneously injected into the flank of female 
nude mice. Tumor volumes were monitored for 31 days. Tumor growth curves are shown 
(left); error bars represent 95% confidence intervals.   
 
B. C. Tumors were exised at the end of the study and tumor weights from each group 
measured (B). Error bars represent 95% confidence intervals. Representative tumors 
from each group (C). 
 
D. Tumor sections were stained with anti-Ki67 and anti-cleaved Caspase 3. Percentage 
positive signal is plotted as a bar graph. Error bars represent 95% confidence intervals. 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                 Figure 25 
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Figure 26. Model of the impact of the CSN6-COP1 axis in regulating 14-3-3σ 
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signaling. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                 Figure 26 
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CHAPTER 5. DISCUSSION 
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   In mammalian cells, COP1 regulates various cellular targets, including stress-
responsive transcription factors, p53 tumor suppressor (13), c-JUN (14-16), acetyl-coA 
carboxylase (17), TORC2  (18), MVP (40) and nucleosome remodeling factor MTA1 (19), 
suggesting its versatile functions. Many COP1 associated proteins remain to be 
characterized.  In this study, our results indicate that COP1 binds and is a novel E3 ligase 
for 14-3-3σ. 
   The known proteins interacting with 14-3-3σ, include Cdk’s (20, 41), p53 (26) and Efp 
(estrogen inducible finger protein) (42), and all play important roles in tumorigenesis. We 
find here that CSN6 is a new 14-3-3σ-associating protein (Fig. 1) and is important in 
promoting cancer growth (Fig. 25) through its binding and degradation of 14-3-3σ (Fig. 8).  
We further determined that CSN6 regulates 14-3-3σ posttransccriptionally by enhancing 
14-3-3σ ubiquitination. CSN6 does not have the conserved RING or HECT domains 
found in well-characterized E3 ligases. Therefore, at issue is how CSN6 causes 14-3-3σ 
downregulation. Thus we searched for potential ligases that could associate with the 
COP9 signalosome and found that the COP1 E3 ligase is a potential candidate. It is 
wothwhile to point out that as an E3 ligase for p53, COP1 drives the ubiquitination and 
proteasomal degradation of p53, thereby maintaining low steady-state levels of p53 in 
unstressed cells (43). In this way, COP1 may antagonize the activity of positive p53 
regulators such as 14-3-3σ, which can stabilize p53 by reducing p53 ubiquitination level. 
Also, COP1 is downregulated in response to DNA damage (44), while 14-3-3σ protein 
level is elevated by DNA damage (25). Together, it is conceivable that COP1 and 14-3-3σ 
may have a functional relationship. Indeed, we observed for the first time that CSN6 
recruits RING containing COP1 to degrade 14-3-3σ. This is based on the observation that 
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CSN6-mediated 14-3-3σ degradation is compromised when COP1 is knocked down with 
shRNA. Importantly, CSN6 not only associates with COP1 but also prevents COP1’s self-
ubiquitination, adding yet another layer of regulation.  
   Although Efp, another RING containing protein, was previously characterized as an E3 
ligase for 14-3-3σ (42), it remains to be studied whether CSN6 also recruits Efp to 
degrade 14-3-3σ. Interestingly, Efp has another activity and seems to serve as an E3 
ligase to add ISG15 (15 Kd protein encoded by an interferon stimulated gene) for 14-3-
3σ-ISGylation (33, 45), but the role of this type of modification in terms of 14-3-3σ protein 
degradation remains unclear. We previously showed that 14-3-3σ is a negative regulator 
of Akt (31). Consistent with this, we found that CSN6 can downregulate the expression of 
14-3-3σ and lead to Akt activation. The observation that CSN6 increases the activity of 
Akt (Fig. 21) is very intriguing. This is the first discovery that links the COP9 signalosome 
with Akt activation. We have shown that CSN6 is involved in 14-3-3σ-mediated Akt 
inhibition, which in turn antagonizes FOXO-meditated transcriptional activity for pro-
apoptotic genes (Fig. 22, 23). Our mechanistic studies of CSN6-mediated 14-3-3σ 
downregulation explains how CSN6 can activate Akt in our proposed model (Fig. 26). 
This study shows that CSN6 positively regulates Akt and promotes Akt-mediated cell 
survival to prevent apoptosis. Clearly, the CSN6-Akt link will be an important molecular 
target for rational cancer therapy. Our primary breast cancer studies showed that CSN6 is 
amplified in 75% of primary breast cancers (39). Also, COP1 and 14-3-3σ inversely 
correlate in primary pancreatic and breast cancer (46). Together, it demonstrates that the 
CSN6-COP1-14-3-3σ-axis is deregulated in cancer. Here, we show that adenoviral gene 
delivery of 14-3-3σ can inhibit tumorigenicity mediated by CSN6 activity in cancer models 
(Fig. 25). Also, similar results were observed in that 14-3-3σ can compromise 
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tumorigenicity mediated by COP1 activity in xenograft cancer models (46). In conclusion, 
since both CSN6 and COP1 are involved in degrading 14-3-3σ, promoting cell survival 
and increasing tumorigenicity, targeting the CSN6-COP1 axis may be a useful therapeutic 
strategy for cancer intervention. 
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